GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were functionally cured of the virus.